Femasys (FEMY) AI Stock Analysis

• Market Cap: $46.54M
• Dividend Yield: N/A
• Average Volume (3M): 2.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 63.53%
• EPS Growth: 12.49%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.10
• Shares Outstanding: 58,479,824
• 10 Day Avg. Volume: 1,412,628
• 30 Day Avg. Volume: 2,456,586
• PEG Ratio: 0.13
• Price to Book (P/B): 10.63
• Price to Sales (P/S): 15.04
• P/FCF Ratio: -1.21
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: 8.88
• Enterprise Value/Gross Profit: 20.96
• Enterprise Value/Ebitda: -1.08
• 1Y Price Target: $5.83
• Price Target Upside: 628.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.55
• Revenue Forecast (FY): $3.62M

• Rating: 49 Neutral
• Price Target: $0.79 ▼(-0.88% Downside)

Femasys's overall stock score is primarily influenced by its challenging financial performance, with significant issues in profitability and cash flow management. However, positive corporate events, including FDA approvals and strategic orders, provide a counterbalance, indicating potential for future growth. Technical analysis and valuation suggest cautious optimism, with mixed momentum and a negative P/E ratio.

Positive Factors

FDA Clearance for FemVue

FDA clearance for FemVue enhances Femasys's product portfolio, reinforcing its market position in women's health diagnostics and potentially driving long-term revenue growth.

International Expansion

The major order for FemBloc in Europe signals successful international expansion, increasing market reach and potential revenue streams in key regions.

Strategic Financing

Securing $12 million in financing enhances financial flexibility, allowing Femasys to manage debt and invest in growth initiatives, supporting long-term stability.

Negative Factors

Profitability Challenges

Negative profit margins indicate ongoing challenges in achieving profitability, which could hinder reinvestment and growth potential if not addressed.

Cash Flow Issues

Negative cash flows limit Femasys's ability to fund operations and growth, necessitating improved cash management to ensure financial health.

Leadership Change

The retirement of a long-term COO may disrupt operational continuity and strategic execution, requiring effective succession planning to maintain leadership stability.

Femasys Business Overview & Revenue Model

Company Description

Femasys (FEMY) is a biotechnology company focused on advancing women's health by developing innovative medical devices and solutions for reproductive health. The company operates primarily in the healthcare sector, specializing in products that address various aspects of female fertility and contraception. Femasys's core offerings include its proprietary systems for non-surgical treatment options, which aim to improve accessibility and effectiveness for women seeking reproductive health solutions.

How the Company Makes Money

Femasys generates revenue primarily through the sale of its medical devices and systems designed for women's reproductive health. The company's revenue model is based on direct sales to healthcare providers, hospitals, and clinics that utilize its innovative technologies. Additionally, Femasys may engage in partnerships with other healthcare organizations and distributors to expand its market reach and enhance product visibility. Key revenue streams include product sales from its core offerings and potential licensing agreements or collaborations with larger medical companies that can leverage Femasys's technology in broader applications. The company may also benefit from grants or funding aimed at supporting women's health initiatives, further contributing to its financial performance.

Femasys Financial Statement Overview

Summary

Femasys shows revenue growth but struggles with profitability and cash flow. Negative net profit margins, EBIT margins, and cash flow deficits are concerning. Improved leverage management is a positive, but overall financial health is weak.

Income Statement

Femasys shows a positive revenue growth rate of 9.25% TTM, indicating some potential for growth. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has decreased significantly from previous years, which is concerning for long-term sustainability.

Balance Sheet

The debt-to-equity ratio has improved to 1.79 TTM from a high of 3.23, suggesting better leverage management. However, the return on equity remains negative, indicating inefficiencies in generating returns from equity. The equity ratio has decreased, reflecting a higher reliance on debt financing.

Cash Flow

Femasys's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is somewhat aligned with net income, but both are negative. The free cash flow growth rate is negative, highlighting ongoing cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.06M	1.63M	1.07M	1.21M	1.18M	1.04M
Gross Profit	873.85K	1.08M	691.90K	764.28K	809.30K	731.38K
EBITDA	-17.01M	-16.33M	-13.17M	-10.49M	-6.55M	-5.80M
Net Income	-19.80M	-18.82M	-14.25M	-11.39M	-7.54M	-6.91M
Balance Sheet
Total Assets	16.29M	12.45M	27.76M	16.90M	28.58M	7.61M
Cash, Cash Equivalents and Short-Term Investments	4.57M	3.45M	21.72M	12.96M	24.78M	3.32M
Total Debt	8.43M	7.44M	6.70M	543.72K	990.21K	2.06M
Total Liabilities	11.73M	10.14M	9.40M	1.65M	2.24M	4.08M
Stockholders Equity	4.56M	2.30M	18.35M	15.24M	26.33M	3.53M
Cash Flow
Free Cash Flow	-20.08M	-20.21M	-11.42M	-11.14M	-8.24M	-4.96M
Operating Cash Flow	-19.58M	-19.44M	-11.28M	-10.73M	-7.93M	-4.93M
Investing Cash Flow	-544.00K	-847.76K	-143.92K	-407.48K	-306.87K	968.32K
Financing Cash Flow	17.08M	2.03M	20.18M	-681.64K	29.70M	871.65K

Femasys Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.80, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.68 is Neutral, neither overbought nor oversold. The STOCH value of 31.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.

Femasys Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	58 Neutral	$7.02M	40.95	5.90%	―	-4.99%	-19.10%
POCI	52 Neutral	$32.63M	-4.94	-57.98%	―	13.67%	-37.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FEMY	49 Neutral	$46.54M	-1.11	-376.23%	―	63.53%	12.49%
RVP	46 Neutral	$24.55M	-3.68	-8.05%	―	-0.95%	58.17%
NXGL	43 Neutral	$16.84M	-4.12	-58.34%	―	73.38%	34.87%
MLSS	41 Neutral	$24.27M	-3.52	-136.47%	―	0.59%	-39.76%

Femasys Corporate Events

Femasys Gains FDA Clearance for FemVue Diagnostic Device

On December 18, 2025, Femasys Inc. reported that it had received 510(k) clearance from the U.S. Food and Drug Administration for its FemVue Controlled diagnostic device, a next-generation solution for controlled contrast delivery during ultrasound imaging to evaluate fallopian tube status. The device combines features of the company’s original FemVue and FemChec technologies into a single FDA-cleared platform, supporting multiple clinical uses such as confirming tubal patency before FemaSeed procedures and is intended to simplify care delivery, enhance workflow efficiency in clinical practice, and streamline manufacturing as Femasys expands its integrated fertility and women’s health product portfolio.

Femasys Secures Major Order for FemBloc Launch

On November 6, 2025, Femasys Inc. announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its partnership with Kebomed. This order marks continued progress in expanding FemBloc’s presence across key European markets, reflecting growing international momentum for this innovative, non-surgical permanent contraceptive solution. FemBloc, a first-of-its-kind non-surgical solution for permanent birth control, addresses a significant unmet need in women’s reproductive health by providing a safer, more convenient, and affordable option compared to surgical sterilization.

Femasys Secures $12 Million Through Private Placement

Femasys Inc. announced on November 3, 2025, that it has entered into a Securities Purchase Agreement with accredited investors to raise $12 million through a private placement of senior secured convertible notes and warrants. The proceeds will be used to repay existing debt and for general corporate purposes, with company insiders participating in the investment. The agreement grants the lead lender a board nomination right and includes customary covenants and restrictions.

Femasys Receives FDA Approval for FemBloc Trial

On November 3, 2025, Femasys Inc. announced it has received FDA approval to advance the final phase of the FemBloc trial, a non-surgical permanent birth control method, marking a significant step towards potential U.S. market entry. Additionally, Femasys secured $12 million in financing, with potential to reach $58 million, which will be used to refinance existing debt and support the commercialization of its fertility and birth control portfolio, reflecting strong investor confidence in the company’s mission to transform women’s health.

Femasys Meets Nasdaq Equity Requirement After Offering

On May 19, 2025, Femasys Inc. received a notice from Nasdaq indicating that its common stock had fallen below the minimum market value requirement for continued listing. However, after a recent offering and warrant exercises, the company reported a pro forma stockholders’ equity of approximately $5.2 million as of October 15, 2025, meeting Nasdaq’s minimum requirement. Nasdaq will continue to monitor Femasys’ compliance, and failure to maintain these standards could result in delisting.

Femasys COO Daniel Currie Announces Retirement

On October 13, 2025, Daniel Currie, Chief Operating Officer of Femasys Inc., announced his retirement effective December 15, 2025, after over 20 years with the company. His departure is due to personal health reasons and a desire to focus on family. The company has entered into a Separation Agreement with Currie, ensuring the vesting of unvested stock options and continuation of health benefits through 2026. The Board of Directors expressed their gratitude for his leadership and service.